2.49  -0.19 (-7.09%)		10-14 16:00
Open: 2.675 High: 2.675 Volume: 853,129		Pre. Close: 2.68 Low: 2.45 Market Cap: 227(M)

Short term
Mid term
Targets	6-month :	3.66	1-year :	4.16
Resists	First :	3.13	Second :	3.56
Pivot price	3
Supports	First :	2.45	Second :	2.03
MAs	MA(5) :	2.77	MA(20) :	3.11
	MA(100) :	3.56	MA(250) :	3.68
MACD	MACD :	-0.3	Signal :	-0.2
%K %D	K(14,3) :	6.5	D(3) :	12.7
RSI	RSI(14): 22.4
52-week	High :	5.15	Low :	2.09

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SABS ] has closed below the lower bollinger band by 6.9%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 59% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	2.68 - 2.7	2.7 - 2.71
Low:	2.41 - 2.43	2.43 - 2.45
Close:	2.46 - 2.49	2.49 - 2.52

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Wed, 14 Oct 2026
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference - Yahoo Finance

Tue, 13 Oct 2026
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes - Yahoo! Finance Canada

Tue, 13 Oct 2026
symbol__ Stock Quote Price and Forecast - CNN

Thu, 01 Oct 2026
Sab Biotherapeutics Inc (SABS-Q) Stock Price and News - The Globe and Mail

Tue, 22 Sep 2026
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes - GlobeNewswire

Fri, 18 Sep 2026
Tax withholding trims SAB Biotherapeutics (SABS) CMO stake - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	91 (M)
Shares Float	62 (M)
Held by Insiders	0.7 (%)
Held by Institutions	75.3 (%)
Shares Short	4,290 (K)
Shares Short P.Month	4,120 (K)

EPS	-1.29
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.56
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-33.5 %
Return on Equity (ttm)	-11.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.54
Sales Per Share	0
EBITDA (p.s.)	-0.76
Qtrly Earnings Growth	0 %
Operating Cash Flow	-54 (M)
Levered Free Cash Flow	-29 (M)

PE Ratio	-1.94
PEG Ratio	0
Price to Book value	0.96
Price to Sales	0
Price to Cash Flow	-4.21

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.